UCD National Virus Reference Laboratory

Publications

The global spread of HIV-1 subtype B epidemic.

Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, Albert J, Lawyer G, Hamouda O, Struck D, Vercauteren J, Wensing A, Alexiev I, Åsjö B, Balotta C, Gomes P, Camacho RJ, Coughlan S, Vandamme AM, Paraskevis D

Infect Genet Evol. 2016 Dec;46:169-179

December 2016
The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors.

Nguyen LT, Gray E, O'Leary A, Carr M, De Gascun CF; Irish Hepatitis C Outcomes Research Network (ICORN)

PLoS One. 2016 Oct 6; 11(10):e0163900

October 2016
HIV-1 in Monocytes and Macrophages: An Overlooked Reservoir?

Hassan J, Browne K, De Gascun C

Viral Immunol. 2016 Nov;29(9):532-533

August 2016
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient

Sevastianova K, Dean J, Bannan C, Coghlan M, Farrell G, Murray C, De Gascun CF, Bergin C

J Clin Virol. 2016 Sep;82:66-69

June 2016
High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme

Gray E, O'Leary A, Stewart S, Bergin C, Cannon M, Courtney G, Crosbie O, DeGascun CF, Fanning LJ, Feeney E, Houlihan DD, Kelleher B, Lambert JS, Lee J, Mallon P, McConkey S, McCormick A, McKiernan S, McNally C, Murray F, Sheehan G, Norris S; Irish Hepatitis C Outcomes and Research Network (ICORN).

J Hepatol. 2016 Aug;65(2):446-8

April 2016
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 R

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group.

Clin Infect Dis. 2016 Jul 1;63(1):122-32

April 2016
Mumps outbreaks in a highly vaccinated population: Investigation of a neutralization titre against the current circulating wildtype genotype G5 mumps virus

KENNY L., O'KELLY E, CONNELL J., DE GASCUN C., HASSAN J.

J Clin Virol. 2016 Jan;74:8-12

January 2016
Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals

30. Nguyen LT, Hall N, Sheerin D, Carr M, De Gascun CF; Irish Hepatitis C Outcomes Research Network

Antivir Ther. 2016;21(5):447-53

January 2016
Pregnancy Outcomes of Mothers with Detectable CMV-Specific IgM Antibodies: A Three-Year Review in a Large Irish Tertiary Referral Maternity Hospital.

Drew RJ, Stapleton P, Abu H, Healy E, Ferguson W, De Gascun C, O'Gorman J, Eogan M

Infect Dis Obstet Gynecol. 2015

November 2015
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

Hofstra LM et al

Clin Infect Dis. 2016 Mar 1;62(5):655-663

November 2015

Pages